PROCEPT BioRobotics (NASDAQ:PRCT) used its 2026 Analyst Day to outline what management characterized as a large, underpenetrated opportunity in benign prostatic hyperplasia (BPH), a developing ...

Company outlines path to leadership in BPH, including near-term focus on procedure growth through patient-centric solutions and increased ...

The Company will report financial results for the fourth quarter of 2025 after market close on Wednesday, February 25, 2026. The Company’s management will host a corresponding conference call ...

PROCEPT BioRobotics (PRCT) is back in focus after its Q4 2025 revenue miss, softer 2026 outlook, and sharp share price reaction, even as management pointed to strong procedure growth and major ...

Analysts expect PROCEPT BioRobotics to report an earnings per share (EPS) of $-0.32. PROCEPT BioRobotics bulls will hope to ...

​PROCEPT BioRobotics Corporation (NASDAQ:PRCT) is one of the Overlooked Small Cap Stocks to Buy Now. Wall Street is positive ...

We came across a bullish thesis on PROCEPT BioRobotics Corporation on Notes From The Beauty Contest’s Substack by ...

Q4 2025 earnings call recap: revenue, procedure growth, 2026 guidance, margin drivers & risks from sales changes—read now.

PROCEPT BioRobotics Corp. PRCT shares are down during Thursday’s premarket session following the company’s recent financial results and updates on its revenue guidance. Performance Metrics In its ...

Full-year 2025 revenue guidance was updated to approximately $323 million, reflecting 44% growth compared to 2024. This includes US system revenue of $95 million, driven by greenfield sales and some ...

PROCEPT BioRobotics Corporation (PRCT) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2025. This widely-known ...

Procept makes the AquaBeam Robotic System, which is designed to be used in performing minimally invasive urology surgeries. The company's first-quarter results were positive, for the most part.